heart valvular disease
Conditions
Interventions
Experimental group:The postoperative patient-controlled analgesic formula of patients in the experimental group was sufentanil 2.5ug/kg + dexmedetomidine 2.5ug/kg + esketamine 1mg/kg+antiemetics
Control group:The postoperative patient-controlled analgesic formula of patients in the control group was sufentanil 2.5ug/kg + dexmedetomidine 2.5ug/kg +antiemetics
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) The subject voluntarily and signed the informed consent form of this trial; (2) 18 years old= age =70 years old, gender is not limited; (3) ASA I-III; (4)18 kg/m2=BMI=30 kg/m2; (5) Elective surgery for valvular heart disease under cardiopulmonary bypass.
Exclusion criteria
Exclusion criteria: (1) Known or suspected allergy to esketamine or related components; (2) Coronary atherosclerotic heart disease (stable angina, unstable angina, myocardial infarction within 6 months before surgery) or cardiomyopathy; (3) Systemic infectious diseases, such as infective endocarditis and sepsis; (4) Patients with neurological diseases, such as cranial tumors, cranial hypertension, cerebral aneurysm, epilepsy, and cerebrovascular accidents (such as cerebral hemorrhage, cerebral infarction); (5) Those with combined psychiatric disorders (schizophrenia, mania, depression, bipolar disorder, Alzheimer's) and a history of long-term use of psychotropic drugs; (6) Endocrine system diseases (poorly controlled diabetes mellitus (fasting blood glucose= 11.1mmol/L and/or random blood glucose =13.6mmol/L), hyperthyroidism, hypothyroidism, Cushing's syndrome, pheochromocytoma, primary aldosteronism); (7) Patients with intraocular pressure increased disease (such as glaucoma) and open eye trauma; (8) abnormal liver function (ALT or AST= 2.5 times the upper limit of normal value, TBIL = 1.5 times the upper limit of normal value); (9) abnormal renal function (Cr= 1.2 times the upper limit of normal value or dialysis treatment within 28 days before surgery); (10) History of drug use or alcohol abuse within 2 years before surgery; (11) Other circumstances that the researcher determines are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain scores;Anxiety-depressive conditions; | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of postoperative recovery;Whether nausea and vomiting or not;Whether or not to use salvage analgesics;Length of ICU stay;Length of hospital stay;The length of time the endotracheal tube is tubed; | — |
Countries
China
Contacts
Public ContactZongbin Song
Xiangya Hospital, Central South University
Outcome results
None listed